Retatrutide: difference between revisions
Diff·revision 12 → 13·04:30, 5 Nov 2024
Difference between revision 12 and revision 13 of Retatrutide. 2 lines changed; the page grew by 170 bytes.
| Revision 12 — 09:43, 19 Oct 2024 CiteBot (talk) bot: repair redlinked category 3,907 bytes +425 | Revision 13 — 04:30, 5 Nov 2024 CagriCass (talk) correct the dose ladder — the maintenance dose is not the maximum dose 4,077 bytes +170 | ||
|---|---|---|---|
| 1 | {{Infobox compound | 1 | {{Infobox compound |
| 2 | | name = Retatrutide | 2 | | name = Retatrutide |
| + | 3 | | subtitle = Investigational | |
| 3 | | image = peptide-chain.svg | 4 | | image = peptide-chain.svg |
| 4 | | caption = A GIP-based backbone engineered for balanced activity at three class B receptors. | 5 | | caption = A GIP-based backbone engineered for balanced activity at three class B receptors. |
| ⋮ | ⋮ | ||
| 12 | | Molar mass = ≈4,731 g·mol⁻¹ | 13 | | Molar mass = ≈4,731 g·mol⁻¹ |
| 13 | }} | 14 | }} |
| + | 15 | {{hatnote|Retatrutide is investigational and is not approved for use in any indication. For the two-receptor case, see [[Tirzepatide]].}} | |
| 14 | 16 | ||
| 15 | '''Retatrutide''' (development code '''LY3437943''') is an investigational 39-residue peptide that agonises three class B receptors: the receptor for [[Glucose-dependent insulinotropic polypeptide]], the [[GLP-1 receptor]], and the [[Glucagon|glucagon]] receptor. It is not approved for use in any indication and is under phase 3 evaluation.{{r|coskun2022}} | 17 | '''Retatrutide''' (development code '''LY3437943''') is an investigational 39-residue peptide that agonises three class B receptors: the receptor for [[Glucose-dependent insulinotropic polypeptide]], the [[GLP-1 receptor]], and the [[Glucagon|glucagon]] receptor. It is not approved for use in any indication and is under phase 3 evaluation.{{r|coskun2022}} |